Results 181 to 190 of about 4,123 (263)

Dynamics of Body Composition and Metabolic Risk in Adolescents With Obesity Under GLP‐1 Receptor Agonist Therapy

Acta Paediatrica, Volume 115, Issue 8, Page 1726-1736, August 2026.
ABSTRACT Aim To explore changes in body composition in adolescents with obesity treated with glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) and their association with metabolic syndrome (MetS) components. Methods This real‐world retrospective study included adolescents (12–18 years) with obesity who received multidisciplinary lifestyle‐based ...
Adar Lopez, Liat Perl, Eyal Cohen‐Sela, Ophir Borger, Yael Issan, Hagar Interator, Erez Azoulay, Hadar Moran‐Lev, Ronit Lubetzky, Shira Zelber‐Sagi, Yael Lebenthal, Avivit Brener   +11 more
wiley   +1 more source

Seasonally structured drone data for shoreline change around a hybrid living shoreline project. [PDF]

Sci Data
Pettyjohn S, Sirianni H, Sirianni MJ, Burchi BMJ, Gittman RK.   +4 more
europepmc   +1 more source

Sustained Clinical Improvement in Birch Pollen Allergy After Two Pre‐Seasonal Short Courses of Allergen‐Specific Immunotherapy: A Long‐Term Open‐Label Extension Study

Clinical &Experimental Allergy, Volume 56, Issue 8, Page 893-903, August 2026.
3 years follow‐up study to a DBPC dose‐finding trial investigating subcutaneous immunotherapy with T502 in birch‐pollen induced allergic rhinoconjunctivitis. 154 birch‐pollen allergic adults received short‐course treatment of 10,000 mTU/mL of T502 for 2 years and were observed during the next season without treatment.
Ralph Mösges, Friederike Hüffmeier, Ludger Klimek, Oliver Pfaar, Christian Neuhof, Anna Rybachuk, Cengizhan Acikel, Hacer Sahin, Silke Allekotte, Sandra del Pozo, José Luis Subiza, Miguel Casanovas, Mandy Cuevas, Laura Day, Lea Radtke, Esther Raskopf   +15 more
wiley   +1 more source

Does Frequency of Temporomandibular Disorders Pain Influence on Physical and Emotional Function? [PDF]

J Oral Rehabil
Chamani G, Gourie N, Osman ZZ, Lahdo P, Barjandi G, Ernberg M.   +5 more
europepmc   +1 more source

Safety and Pharmacokinetics of Single and Multiple Ascending Doses of Olamkicept up to 2400 mg in Healthy Men: Phase I, Randomized, Placebo‐Controlled, and Double‐Blind Trial

Clinical and Translational Science, Volume 19, Issue 8, August 2026.
ABSTRACT Olamkicept is a first‐in‐class fully human fusion protein that selectively inhibits trans interleukin (IL)‐6 signaling. Previous phase I clinical trials demonstrated that single doses up to 750 mg and multiple doses up to 600 mg were safe and well tolerated in healthy men and women.
Stanislav Ignatenko, Alla Radicke, Katharina Bruzelius, Michael Falkenberg, Lars‐Erik Kyhl, Signe Møgelmose, Arjun Ravi, Philippe Pinton   +7 more
wiley   +1 more source

Evaluation of the Safety, Efficacy and Pharmacokinetics of BGM0504 in Chinese Adults With Type 2 Diabetes: A Multicentre, Randomised, Controlled and Double‐Blind Phase II Trial

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 7073-7082, August 2026.
ABSTRACT Aim This study aimed to evaluate its safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy in Chinese adults with T2DM and to preliminarily compare its efficacy and safety with semaglutide through multiple subcutaneous injections. Materials and Methods In this multicentre, randomised, placebo‐controlled and semaglutide‐positive‐
Ping Jin, Linong Ji, Yangqing Huang, Haifeng Ding, Daosheng Xie, Xiaohui Jiang, Xuemei Yuan, Zhao Cao, Haibin Zhang, Jiandong Yuan   +9 more
wiley   +1 more source

Assessment of Common Oral Behaviors in Patients with Temporomandibular Joint Disorders and Their Relationship to Psychosocial Factors. [PDF]

Dent J (Basel)
Hoa NN, Viet Hai H, Binh TT, Dong TT, Minh Quyen TT, Do T.   +5 more
europepmc   +1 more source

Survodutide for the Treatment of Obesity Disease in Japanese Participants: Rationale, Design and Baseline Characteristics of the Phase 3 SYNCHRONIZE‐JP Trial

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 6595-6606, August 2026.
ABSTRACT Aims There is an unmet need for effective pharmacotherapy for obesity disease management in Japan. Survodutide is a novel glucagon receptor/glucagon‐like peptide‐1 receptor (GLP‐1R) dual agonist with the potential to induce greater weight reductions than GLP‐1R mono‐agonists. We report the design and baseline participant characteristics of the
Koutaro Yokote, Toshimasa Yamauchi, Yasushi Fukushima, Yoji Takatsuka, Marie Kato, Shijia Yan, Takayoshi Inoue, Luiza Borowska, Martina Brueckmann, Wataru Ogawa, on behalf of the SYNCHRONIZE‐JP Trial Investigators   +10 more
wiley   +1 more source

Discrimination, depressive symptoms, and prescription opioid misuse among adults with chronic pain who engage in hazardous drinking. [PDF]

Am J Drug Alcohol Abuse
Carlin VE, Lape EC, Deyo AG, Ripley GH, Polhill SE, Zale EL, Nam JK, Zvolensky MJ, Maisto SA, Ditre JW.   +9 more
europepmc   +1 more source